Anzeige
Meldung des Tages: Hydrograph bei 8,30 $: Jetzt 20-Mio.-Graphen-Deal + 50 % Move: Plaid der Nächste?

Inhibrx Biosciences News

Aktie
WKN:  A40C2U ISIN:  US45720N1037 US-Symbol:  INBX Branche:  Biotechnologie Land:  USA
129,02 $
+3,96 $
+3,17%
110,01 € 30.04.26
Depot/Watchlist
Marktkapitalisierung *
987,31 Mio. €
Streubesitz
7,31%
KGV
-9,60
Index-Zuordnung
-

Inhibrx Biosciences News

21.04.26 - PR Newswire
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer PR Newswire
20.04.26 - PR Newswire
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer PR Newswire
19.03.26 - PR Newswire
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results PR Newswire
02.03.26 - PR Newswire
Inhibrx Announces Participation in Upcoming Scientific Conference
Inhibrx Announces Participation in Upcoming Scientific Conference PR Newswire
16.12.25 - PR Newswire
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program PR Newswire
14.11.25 - PR Newswire
Inhibrx Reports Third Quarter 2025 Financial Results
Inhibrx Reports Third Quarter 2025 Financial Results PR Newswire
04.11.25 - PR Newswire
Inhibrx Announces Participation in Upcoming Scientific Conferences
Inhibrx Announces Participation in Upcoming Scientific Conferences PR Newswire
23.10.25 - PR Newswire
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and ...
22.10.25 - PR Newswire
Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer ...
13.08.25 - PR Newswire
Inhibrx Reports Second Quarter 2025 Financial Results
Inhibrx Reports Second Quarter 2025 Financial Results PR Newswire
14.05.25 - PR Newswire
Inhibrx Reports First Quarter 2025 Financial Results
Inhibrx Reports First Quarter 2025 Financial Results PR Newswire

Newssuche

Videos

newspaper
26.04.26
Big Fish Strategy Einführung
Strategie-​Paket inklusive Live-​Webinar am 3.5., Videoaufzeichnung, Unterlagen und Nachbetreuung JETZT ... Mehr »